Archive for 2010 Archive for 2009 Archive for 2008 Archive for 2007 Archive for 2006 Archive for 2005 Archive for 2004 Archive for 2003
Archive for 2002 Archive for 2001 Archive for 2000 Archive for 1999 Archive for 1998 1997 1995-1996  


2007 Archive
(listed in reverse chronological order)

February 28th, 2008

Bushinsky  

Block  

Llach  

Mehrotra  
Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains    
David Bushinsky, MD (moderator); Geoffrey Block, MD, CCRI; Francisco Llach, MD; Rajnish Mehrotra, MD, FACP, FASN.
(ASN Renal Week Official Symposium, 2007).
Panel Discussion: What are the factors that promote vascular calcification in early CKD and in ESRD? How does vascular calcification affect prognosis? Should we screen for vascular calcification? If so, how? If yes, then how do we use this information? What should the target serum phosphate levels be as CKD progresses from stage 3 through 5? How good is the data suggesting lower phosphate targets? What are the various phosphate binder options available? Are they equally effective? Equally potent? Are there patient factors affecting choice of binder? To what extent should we control serum phosphate in predialysis patient? How should this be done? What are the key take-home points?


Fliser  

Aronoff  
The Aging Kidney   
Danilo Fliser, MD; George R. Aronoff, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Fliser: How fast does GFR fall as we age? If GFR the best measure of renal function in the elderly? What other changes occur in the kidneys as we age? How is the fall in GFR related to comorbidity? To what extent is cystatin a better measure of GFR in the elderly? Aronoff: How do we approach drug dosing in the elderly? What happens to body composition and how does this affect dose? Is liver metabolism of drugs affected? If so, how? What about pharmacodynamics? What is the Beers list of drugs? Which drugs are best avoided in the elderly? What are practical ways of reducing drug exposure in this population?



ANNA CE

(Article Free, $CE)
Learning from Stories of People with Chronic Kidney Disease
(Vol 35/No. 1. Expires 02/20/2010)
Anita E. Molzahn, PhD, RN; Anne Bruce, PhD, RN; Laurene Sheilds, PhD, RN
1.3 hr

Cognitive Function and Adherence of Older Adults Undergoing Hemodialysis
(Vol 35/No. 1. Expires 02/20/2010)
Debra J. Hain, DNS, ARNP, GNP, BC
1.4 hr



ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 2 of 2)

Principles of Bioethics: Justifying Research
Bernard Lo, MD

Debate: Does Routine Screening of Dialysis Access Reduce Risk of Thrombosis?
Laura M. Dember, MD, FASN

Decision Analysis and Cost-Effectiveness Analysis: Taking It to Another Level
Neil R. Powe, MD, MPH, MBA, FASN

Genetic Epidemiology: A New Frontier
Donald W. Bowden, PhD

Putting It All Together: Journal Club #2
Kirsten L. Johansen, MD

Biostatistics Workshop Part #2: Everything You Always Wanted to Know About Biostatistics, But Were Afraid to Ask
Charles E. McCulloch, PhD



February 15th, 2008

London  

Langman  

Ketteler  
Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions    
Gérard M. London, MD (moderator): Craig B. Langman, MD; Markus Ketteler, MD.
(ASN Renal Week Official Symposium, 2007).
Langman: What is the pathogenesis of mineral bone disorder in CKD? As GFR falls, at what point does serum Pi increase? What is the comparative efficacy of currently used Pi binders? What's the association between serum Pi levels and cardiovascular risk in ESRD, stage 2-4 CKD, and stage 2 CKD? What percent have coronary calcification at onset of dialysis? What were the conclusions of the DCOR and RIND studies in terms of coronary calcification and survival in patients using sevelamer vs. calcium-containing binders? What are the new data concerning sevelamer carbonate? Ketteler: What is fibroblast growth factor 23, and what is its role in phosphate excretion as GFR falls? How does extracellular phosphate affect vascular smooth muscle biology? What are the pathways for activating vascular smooth muscle transformation into osteoblast phenotypes? What does fetuin-A do? How does sevelamer affect fetuin-A levels? What is the role of matrix Gla protein and pyrophosphate in preventing calcification?


Burnett  

Fowler  

Gheorghiade  
Challenges in Volume Management. Optimizing Care in Patients with Heart Failure and Renal Dysfunction    
John C. Burnett, MD; Michael B. Fowler, MBBS, FRCP; Mihai Gheorghiade, MD
(ASN Renal Week Official Symposium, 2007).
Burnett: What is the prevalence of CKD in patients with CHF? What is the cardiorenal syndrome? What are its principal mechanisms? How are ANP and BNP involved? How is BNP activation impaired in CHF? How are aldosterone and AVP involved in heart failure? Fowler: Which of the common pharmacologic treatments for heart failure impact on survival and other hard outcomes? Digoxin? Diuretics? Beta-blockers? ACE-I, ARB? Aldosterone blockers? Nitrates-hydralazine? Do implantable defibrillators improve survival? What is the risk-predictive value of a widened QRS interval? What is cardiac resynchronization therapy? What are new treatment methods on the horizon, including vasopressin antagonists, adenosine antagonists, aliskiren, and newer intotropic agents? Gheorghiade: What is the role of pulmonary congestion in heart failure? What are the therapeutic options? How do treatments with diuretics vs. vasopressin antagonists differ in terms of effects on urinary parameters and serum sodium? What is the prognostic importance of hyponatremia in heart failure? What do the treatment trials with vasopressin antagonists, especially using tolvaptan, show in terms of both intermediate and hard outcomes?


Henrich  
Cardiovascular Disease in End Stage Renal Disease Patients   
William L. Henrich, MD, MACP.
(ASN Board Review Course, August, 2007.)
Henrich: What are the main cardiovascular risks in patients with CKD? What are the proposed mechanisms of LVH, including concentric and eccentric hypertrophy, and systolic and diastolic dysfunction? What are the causes for sudden death? What is the role of myocardial intermyocyte fibrosis? What did the fosinopril and ramipril trials show? Are biomarkers useful? Why was the 4-D trial negative? Are statins useful in early CKD? What is the role for carvedilol? More frequent dialysis? Is there an advantage for CABG over stents in ESRD patients? What are the basic management guidelines for cardiovascular disease in CKD patients?



ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 1 of 2)

E is for Epidemiology: The Key Principles
Harold I. Feldman, MD, FASN

Case-Control Studies: Low Cost/High Impact
Rulan S. Parekh, MD, FASN

Cohort Studies: From the Beginning to the End
Ravi I. Thadhani, MD, MPH

Randomized Controlled Trials: Good as Gold
Christoph Wanner, MD

Biostatistics Workshop Part #1: How Things Actually Work
Tom H. Greene, PhD

Biostatistics Workshop Part #2: How Things Actually Work
Tom H. Greene, PhD

Meta-Analysis: When One is Not Enough
Amit Garg, MD, PhD

Putting It All Together: Journal Club #1
Mary B. Leonard, MD



January 30th, 2008

Knopp  

Persson  

Perazella  
Contrast Media and CKD: What You Should Know About Contrast-Induced Nephropathy and Nephrogenic Systemic Fibrosis    
Norbert Lameire, MD (moderator); Pontus B. Persson, MD, PhD; Michael V. Knopp, MD, PhD; Mark A. Perazella, MD
(ASN Renal Week Official Symposium, 2007).
Persson: What is the definition of contrast-induced nephropathy (CIN)? How can an acute decrease in GFR result in a creatinine elevation that peaks several days later? Is it the osmolality of these agents or their viscosity that's at fault? How do they cause renal damage? How do the affect blood flow through the vasa recta? Tubuloglomerular feedback? What is the osmolality and viscosity of commonly used contrast agents? What do clinical studies tell us? Why is renal failure lower with a low-osmolar, but above iso-isosmolar, agent (ioxaglate) compared to an isosmolar agent (iodixanol)? Knopp: What are the choices of imaging procedures in renally impaired patients? How do we use them to assess morphology and function? What are the main categories of MR contrast agents? Perazella: How is nephrogenic systemic fibrosis (NSF) defined? When was it first noticed? What are the symptoms? What parts of the body are affected? Which parts are spared? What are predisposing causes? Does it occur in stage 1-4 CKD? How do we diagnose NSF? With which MR agents is it most common? Least common? What guidelines can we follow in using these agents?


Roy  

Besarab  

Amerling  
New Developments in Anemia Management in Chronic Kidney Disease    
Dr. Adeera Levin, MD (moderator): Cindy Roy, PhD; Anatole Besarab, MD; Richard Amerling, MD, Arnold Berns, MD (discussant)
(ASN Renal Week Official Symposium, 2007).
Roy: How dose iron cycle through the various organs? Where does hepcidin get involved? What is ferroportin? What does hepcidin to to macrophage transport of iron? To iron absorption? What can we learn from transgenic rat models?
Besarab: How has our target Hb evolved as guidelines have been issued over the past 10 years? What is the FDA target? The 2007 KDOQI target? What did the Normalized Hemoglobin Trial, CREATE, and CHOIR show? How can we achieve Hb targets while minimizing cycling? What does KDOQI recommend in patients with ferritins greater than 500? What happened in the DRIVE study, where iron was given to patients with ferritins of 500-1200 ng/mL?
Amerling: When 1 g of ferric gluconate was given to 80 dialysis patients with serum ferritins ranging from 100 - 1500 ng/mL, what where the results on Hb, TSAT, and serum ferritin? What effect did this have on ESA dose?


Bennett  
The Cystic Diseases   
William M. Bennett, MD.
(ASN Board Review Course, August, 2007.)
Bennett: What are the basis of PKD genetics? Clinically, how do ADPKD1, ADPKD2, and ARPKD differ? How do we diagnose PKD? When are ultrasounds falsely negative? Genetic tests? What part of the cell is affected by polycystin? What is the 2-hit theory? What are the renal complications? How should hypertension be treated? What are the cerebrovascular and cardiovascular complications? When should we screen for CV aneurysms? What are the liver and GI complications? What did we learn from the CRISP study about progression? What are the new treatments for PKD? what conditions can cause similar cystic disease in the kidney? What other renal cystic diseases are of importance?



Columbia University

Biopsy Conference: A middle-aged Hispanic male with microhematuria and proteinuria

(Columbia University Nephrology and Pathology Faculty; January, 2008)

A middle-aged Hispanic male had with history of incarceration, occupation as a welder, heroin abuse, presented with proteinuria 3.4 g/day and microhematuria. No DM. Mild HTN. Normal sized kidneys. Negative serological tests. Initial DDx: Membranous, IgA, FSGS. Discussion focus: Hint: IgG deposits were found.
(Edited by Jai Radhakrishnan, MD). (more...)


ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 2 of 2)
Defining AKI
Ravindra L. Mehta, MD, FASN

Pathophysiology of AKI
Bruce A. Molitoris, MD

Pharmacologic Therapy for AKI
Mark D. Okusa, MD, FASN

Contrast-Induced Nephropathy
Paul M. Palevsky, MD, FASN

Abdominal Compartment Syndrome
Lakhmir S. Chawla, MD

Renal Replacement Therapy in AKI: When, What, and How Much
Paul M. Palevsky, MD, FASN

The Hybrid Renal Replacement Therapies
Mark R. Marshall, MBChB

Technical Issues for the Delivery of RRT in the ICU
Paul M. Palevsky, MD, FASN

Pediatric AKI
Stuart Goldstein, MD

Drug Dosing in AKI
Bruce A. Mueller, PharmD

Treatment of Poisonings
David S. Goldfarb, MD, FASN



January 15th, 2008

Berns  

Provenzano  

Szczech  
Navigating the Erythropoietin Stimulating Agent Landscape in CKD-Related Anemia   
Jeffrey S. Berns, MD, FASN; Robert Provenzano, MD; Lynda Szczech, MD. (Moderator: Jeffrey S. Berns, MD)
(ASN Renal Week Official Symposium, 2007).
Berns: What does the recent literature show? CHOIR, CREATE, ACORD, MacDougall, and the 2007 KDOQI workgroup meta-analyses?
Provenzano: How were these issues discussed at the Cardiovascular and Renal Drugs Advisory Committee on ESAs? What were the votes regarding each practice recommendation? What were open questions?
Szczech: Now that the FDA has mandated new black box warnings on ESAs, how does impact our use of these agents? How can we minimize potential side effects of ESAs? What might be our triggers for action? What should the initial dosages be, and when should doses be reduced or held?


Murray  
Critical Care Nephrology   
Patrick Murray, MD.
(ASN Board Review Course, August, 2007.)
Murray: How do we hemodynamically manage sepsis in terms of MAP, CVP, urine output, and mvO2? How can we optimize renal perfusion? Is there evidence that any of the inotropes are better? What should the target MAP be? What are the results regarding vasopressin? Drotrecogin alpha? Corticosteroid use? What is the ideal ventilator strategy, and what are the main pulmonary-renal syndromes? What do the data show about dry vs. wet management?



ANNA CE

Lecture Free
Free CE

Arruda  

Snavely  
Chronic Kidney Disease - Mineral Bone Disorder   
Jose A.L. Arruda, MD, FASN; Jennifer L. Snavely, CRNP-BC, MSN, CNN)
(ANNA Fall Meeting, San Francisco, CA. October, 2007.) 1.25 CE
Arruda: What do observational data suggest about desirable levels of serum PTH, calcium, and phosphorus in CKD patients? What do the vitamin D studies show? Are the analogues different from calcitriol in terms of survival? When is cinacalcet indicated? How does vascular calcification relate to mortality? What did the Treat-to-Goal, RIND, and DCOR studies tell us about calcium-containing phosphate binders versus sevelamer? Snavely: How do we define CKD-Bone Mineral Disorder? As CKD progresses, when do changes in calcium, phosphorus, and PTH occur? How is vitamin D involved? What to the KDOQI clinical practice guidelines suggest in terms of managing elevated PTH as GFR falls? When should we give vitamin D and in what form? What are the practice barriers in addressing bone mineral disorders in CKD patients?


ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 1 of 2)
Ventilators 101: What the Non-Intensivist Needs to Know
Patrick T. Murray, MD, FASN

Acute Lung Injury/ARDS
Kathleen D. Liu, MD

Hemodynamic Monitoring and Volume Management
Lakhmir S. Chawla, MD

Approach to Shock, Vasopressors, and Natriuretic Peptides
Kathleen D. Liu, MD

Advances in the Treatment of Severe Sepsis and Septic Shock
Patrick T. Murray, MD, FASN

An Update on Congestive Heart Failure
Kiran K. Khush, MD

Update in Coagulation: Cell Mediated Coagulation and New Anticoagulants
Lakhmir S. Chawla, MD

Current State of Acute Brain Injury Management
Andrew Davenport, MD

Ethics in the ICU: When Can You Say No?
Douglas B. White, MD, MAS



December 31st, 2007

Palmer  
Electrolyte/Acid-Base Emergencies in the ICU   
Biff F. Palmer, MD.
(ASN Board Review Course, San Francisco; August, 2007.)
Palmer: Case 1: Hyponatremia after traumatic subarachnoid hemorrhage. What is the cause? Case 2: Hyponatremia after trans-urethral resection of the prostate gland. What is the etiology? Why did symptoms worsen with treatment? Case 3. Anion gap metabolic acidosis in a patient with apparently (but not really) compromised bowel. Case 4. Anion gap acidosis in a ventilated patient on lorazepam infusion. Case 5. Extreme hyperkalemia post-operatively in a patient receiving coronary artery bypass surgery. Case 6. Acute renal failure in a post-operative patient after volume expanders. Case 7. Malignant hyperthermia intra-operatively. Case 8. Acute renal failure, anion-gap acidosis, and hyperkalemia post-operatively. Case 9. Hyperkalemia and profound weakness in a post-operative patient. Already know the answers? The CME post-test for this activity will be posted in the coming week.

ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Nephrology Nurses' Perspectives On Difficult Ethical Issues And Practice Guideline for Shared Decision Making
(Vol 34/No. 6. Expires 12/20/2009)
Christy Price Rabetoy, NP; Bradley C. Bair, MS, MStat
1.5 hr

Fatigue in African American Women on Hemodialysis
(Vol 34/No. 6. Expires 12/20/2009)
Amy G. Williams, MSN, RN; Patricia B. Crane, PhD, RN, FAHA; Daria Kring, MSN, RN, BC
1.5 hr



ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CKD and CVD from the Vascular Viewpoint: Merging Basic and Clinical Sciences to Optimize Treatment. (Part 2 of 2)

VI. Renin-Aldosterone Axis
The Other Side of the RAAS Family: Renin Receptors, ACE 2, Ang III in the Kidney
Matthew R. Weir, MD

Renin Redux: Benefits of Blocking This System
Dominic A. Sica, MD

VII. Assessing Risk and Assessing Benefit
Epidemiology: Risky Business
Alan Go, MD

CVD Risk in CKD: Serum Creatinine, Cystatin, and Albuminuria
Josef Coresh, MD, PhD, FASN

VIII. Genetics
Looking Under the Hood: What GRK4 Mutations and Other Genetic Causes of Hypertension Teach Us
Pedro A. Jose, MD, PhD

Beyond Levi Strauss: Genetic Components and Other Clues
David G. Warnock, MD

IX. Vascular Calcification/Vitamin D
Veinus de Milo: How Vessels Calcify
Sharon M. Moe, MD, FASN

Got D? Vitamin D in CKD: Is it Helpful? How Much? How Measured?
Adeera Levin, MD, FRCPC

X. Pregnancy
Clues in Pregnant Hypertensives: Suspects? Venue? Weapons?
Phyllis August, MD, MPH



December 15th, 2007

Chan  
Nocturnal and Frequent Dialysis: Are These the Preferred Therapies for Patients with Cardiovascular Disease?   
Christopher T. Chan, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Chan: Cardiovascular risk is greatly increased in stage 5 CKD patients treated with conventional 3x/week schedules. What are the mechanisms whereby more frequent dialysis, either as short daily or long nocturnal, might alter this outcome? What is the impact of these newer dialysis schedules on intradialytic complications? On systolic and diastolic blood pressure? On left ventricular mass index? What are the differences in effect on LVMI between short daily and long nocturnal schedules? What is the relation to control of serum phosphorus? What are the effects of the more frequent schedules on vascular reactivity? Exercise capacity? Inflammatory markers? Endothelial progenitor cell number?


ASN Renal Week 2007
now in MP3
AUDIOFILE LIST (Renal Week 2007)

2007 Renal Week PGE Course:
CKD and CVD from the Vascular Viewpoint: Merging Basic and Clinical Sciences to Optimize Treatment. (Part 1 of 2)

I. Biology of the Vessel
Endothelial Function/Dysfunction: What Does It Mean and Why Does It Matter?
Michael S. Goligorsky, MD, PhD.

The Vascular "Check-Up": Endothelial Action and Clinical Relevance
Ernesto L. Schiffrin, MD, PhD, FRCPC, FACP

II. Lipids and Vascular Function
Not All Lipids Are Created Equal: Diabetes and CKD
Moshe Levi, MD, FAHA, FASN.

Slip-Sliding Along: Lowering Lipids
Vito M. Campese, MD

III. The CKD Patient
The Other CVD Risk Factor: How to Achieve Goals of Treatment
Hannelore B. Hampl, MD

Case 1: The 51 Year Old AA Woman with a Creatinine of 2.1 and Hyperlipidemia
Raymond R. Townsend, MD

IV. The CVD Patient
Mending Heartbreak in CKD: Succeeding in Secondary Prevention
Mark J. Sarnak, MD, FASN

V. Proteinuria
Why Does the Glomerulus Leak?
Jerry Yee, MD, FASN

Too Much of a Good Thing in the Wrong Place
Stephan J.L. Bakker, MD

Case 2: The 65 Year Old Diabetic with a Prior Stroke
Frank C. Brosius, MD



November 25th, 2007

Chavers  
Sudden Death in Hemodialysis Patients: Epidemiology   
Blanche M. Chavers, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Chavers: What are the factors impacting on sudden death in ESRD patients? What are the demographics? Trends? Is there a race or gender gap? What are the potential causes? What cardiovascular factors are most importantly associated with sudden death? What treatment fators? Which are potentially correctible? What about geographic variation? Do some dialysis chains do better in this area than others?




November 16th, 2007

Tuttle  
Diabetes and Non-insulin Management in CKD   
Katherine R. Tuttle, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Tuttle: What are the new KDOQI guidelines regarding treatment of diabetes in CKD patients? How aggressively should we manage hyperglycemia? When should we use insulin? Which oral medications are of use in CKD and ESRD? Which are contraindicated, and why? Which may have special advantages? Which ones require dosage adjustment? What types of combination therapy are useful?



ANNA CE

Lecture Free
Free CE

Easom  

Juergensen  

Amerling  
Updating Practices in an Evolving IV Iron and Anemia Environment: Practical Solutions. A New Anemia Treatment Paradigm in Favor of the Patient   
Andrea Easom, MA, MNSc, APN, BC, CNN-NP; Peter Juergensen, PA-C; Richard Amerling, MD
(ANNA National Symposium, Dallas, TX. April 2007.) 1.25 CE
Easom: What are we doing and what could we be doing better? How do we organize a team approach to optimize patient hemogloblins? What is annual blood loss on average, and how does this argue for maintenance iron therapy? How do we use a collaborative approach in implementing change? Juergensen: How can we develop and establish a maintenance IV iron protocol to enhance patient outcomes? How do we pilot new protocols and evaluate their effectiveness? What is an example of a simplified protocol? Amerling: How does emerging outcomes information encourage us to rethink the way we treat patients with anemia? What is a more appropriate anemia treatment paradigm based on new data? What are some illustrative case studies?


Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Control of Extracellular Volume and Blood Pressure Are Essential for Optimal Dialysis
Zbylut Twardowski, MD., Garry Reams, MD., Kamyar Kalantar-Zadeh, MD, PhD., Bernard Charra, MD., Wladyslaw Sulowicz, MD

Vascular Access: A Multidisciplinary Approach to AV Fistula Access Care
Anatole Besarab, MD., Jack Work, MD., Arif Asif, MD., Deborah J. Brouwer, RN, CNN., Kathleen Bregel, RN, CNN., Deborah J. Brouwer, RN, CNN., Rosa M. Marticorena, RN, BScN, DCE



October 31st, 2007

Kalantar-Zadeh  
Obesity and Outcomes in Dialysis Patients   
Kamyar Kalantar-Zadeh, MD, PhD, MPH.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Kalantar-Zadeh: Is a heavier BMI better in dialysis patients? How can we reconcile this with data in nonuremic patients? Are there other populations where a higher BMI is protective? If so, what are they? What are the possible reasons for so-called reverse epidemiology in terms of BMI? How robust is this data? What are other areas of apparent reverse epidemiology in CKD patients? What are potential physiologic explanations for the high BMI survivor paradox?


ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Blood Pump Speed vs. Actual or "Compensated" Blood Flow Rate
(Vol 34/No. 5. Expires 10/20/2009)
Helen F. Williams, BSN, RN, CNN; Kirsten Jensen, BSN, RN, CNN; David Gillum, MD; Jose Nabut, MS
1.5 hr

Perceptions of Adult Patients on Hemodialysis Concerning Choice Among Renal Replacement Therapies
(Vol 34/No. 5. Expires 10/20/2009)
Kandace J. Landreneau, PhD, RN, CCTC; Peggy Ward-Smith, PhD, RN
1.5 hr

Adherence in Patients On Dialysis: Strategies for Success
(Vol 34/No. 5. Expires 10/20/2009)
Jean K. Kammerer, BSN, RN, CNN; Glenn Garry, BS; Marguerite Hartigan, MSN, RN; Barbara Carter, MEd, BSN, RN, CNN; Linda Erlich MS, RN
1.5 hr

Updating Practices in an Evolving IV Iron and Anemia Environment: Practical Solutions
(Vol 34/No. 5. Expires 10/20/2009)
Richard Amerling, MD; Andrea Easom, MA, MNSc, APN, BC, CNNNP; Peter Juergensen, PA-C
1.5 hr


Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Optimal vs. Adequate Dialysis (3 talks)
Carl M. Kjellstrand, MD, PhD., Rodney S. Kenley, MS, MM.

Is Increasing Utilization of APD Warranted? (12 talks)
Fredric O. Finkelstein, MD., John M. Burkart, MD., Salim Mujais, MD., Alexandra Voineseu, MD., Dana Negoi, MD., Martin Schreiber, MD.



October 17th, 2007

Beddhu  
Is Obesity a Risk Factor for the Development And Progression of Chronic Kidney Disease?   
Keith C. Norris, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Beddhu: Elevated BMI is supposedly a survival factor in ESRD. Is this true in CKD, or is obesity associated with more rapid progression of renal insufficiency? What did the HDFP (Hyperternsion Detection and Follow Up Study) show? The Physician Health Study? Other large databases? What are the potential mechanisms of kidney damage in obesity? What are the roles of hyperfiltration vs. other aspects of the metabolic syndrome as well as inflammatory mediators? What if we control for the degree of insulin resistance using HOMA? Can weight loss affect progression in CKD patients? Is this clinically desirable? CME will be combined with the next week's talk.



Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Nutrition and Nursing Workshop I
Sue Dickey, MS, RD., Lisa Murphy-Gutekunst, MSEd, RD, CSR, CDN

Incorporating Findings from the Clinical Nursing Assessment into the Individualized Care Plan for Dialysis
Glenda Payne, MS, RN, CNN., Mary Schira, PhD, RN, CS., Mary Zorzanello, MSN, RN, CNN., Brenda F. Patrick, MS, RN, CNN, APRN-BC

The Kidney in Liver Failure
Robert Isom, MD., J”rg Vienken, MD., Isaac Teitelbaum, MD



September 29th, 2007

Norris  
Cocaine and Chronic Kidney injury   
Keith C. Norris, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Norris: What are the complications associated with cocaine use? What are its pharmacokinetics? What are the renal complications and what is their pathogenetic mechanism? How does cocaine modify the course of CKD in the African Ammerican community? What are cocaine's affects in causing rhabdomyolysis, acute and chronic hypertension? What are its effects on the RAAS, catecholamines, thromboxane, and inflammatory mediators?



ANNA CE

Lecture Free
Free CE

Mathers  
Achieving and Maintaining a Phosphate Balance in the Patient With CKD   
Terran Mathers, DNC, RN.
(ANNA National Symposium, Dallas, TX. April 2007.) 1.25 CE
Mathers (Dr. Richard Sherman's slides: What is the pathogenesis of hyperphosphatemia in CKD? How well is phosphate controlled? How does mortality relate to serum levels? What are the 3 factors affecting phosphorus control? What does KDOQI say? Which beverages contain lots of phosphate? What is the role of food additives? How much is removed during dialysis? How is compliance affected by pill burden?
Mathers: What are the various phosphate binder options? What are the advantages and disadvantages of each? How do the non-calcium binders compare? How is binding affected by pH? To what extent is it specific? How is choice of binder related to pill burden? How can nurses become patient advocates against hyperphosphatemia?


ANNA CE

Lecture Free
Free CE

Burrows-Hudson  

Headley  

Campoy  
Standards: The Basis of Care to Manage the Patient with Complications of Chronic Kidney Disease Leading to Cardiovascular Disease   
Sally Burrows-Hudson, MS, RN, CNN; Carol Headley, DNSc, RN, CNN; Sally Campoy, DNP(c), MS, APRN, BC.
(ANNA National Symposium, Dallas, TX. April 2007.) 1.25 CE
Burrows-Hudson: What is the importance of Standards of Practice and Guidelines for Care in the nursing care of patients withe CKD? What are the traditional and non-traditional risk factors for cardiovascular disease? Headley: What is the role of controlling blood pressure and minimizing proteinuria in CKD? What is the nurse's role? What are the recommended lifestyle modifications and pharmaceutical drugs? How is bone metabolism altered? How does this affect calcification and vascular risk? What are the specific dangers of calcification in terms of the cardiovascular system? Campoy: How does anemia impact on cardiovascular disease in CKD? What are potential benefits of anemia treatment? What are the potential risks, and what are the newer target Hb values given the results of the CHOIR and CREATE studies? What is the new 2007 KDOQI recommendation? What are the disorders of cholesterol and triglycerides in CKD patients? When should they be treated, and to what serum levels?


Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Future of HD Access (5 talks)
Dennis Andress, MD., Wladyslaw Sulowicz, MD., Kamyar Kalantar-Zadeh, MD, PhD., Daniel W. Coyne, MD., Peter G. Kerr, MB, BS, PhD

Derangement in Calcium/Phosphorous: Tip of Iceberg Bone, Heart & Hormonal Links: Factors Effecting Morbidity & Mortality (9 talks)
Dennis Andress, MD., Wladyslaw Sulowicz, MD., Kamyar Kalantar-Zadeh, MD, PhD., Daniel W. Coyne, MD., Peter G. Kerr, MB, BS, PhD

The Cutting Edge of Renal Kidney Replacement Therapy: Nanotechnology, Wearable and Bionic (6 talks)
Allen R. Nissenson, MD., Victor Gura, MD., Eli A. Friedman, MD



September 14th, 2007

Perazella  
Proton Pump inhibitors and the Kidney: Critical Review   
Mark A. Perazella, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Perazella: What are the renal issues pertaining to proton-pump inhibitors. Do they affect potassium or proton secretion in the kidney? How are they metabolized? What implications are there for interactions with calcineurin inhibitors? How does their metabolism differ in terms of P450 enzymes? How frequently do they cause acute interstitial nephritis? What are the clinical features? Is steroid treatment beneficial? To what extent is this a clinically significant problem? CME: Will become active next week, as this talk is grouped with the one that follows it.



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part 6 of 7.    Note: Access is FREE for ASDIN members.
Slide Handouts

K-DOQI Update on Vascular Access
Anatole Besarab, MD

Economics of Dialysis Access
Donald Schon, MD, FACP

Future of Nephrology-related Procedures: Where Are We Headed?
Stephen Ash, MD, FACP

Nursing Breakout Session

Safety Concerns in the Interventional Suite
Jay Copelan, RT

Monitoring & Surveillance Programs What Do They Mean?
Janet Holland, RN, CNN

Vascular Access Education: Do we need this tool?
Donna Merrill, RN

It Takes Two to Tango!
Deborah Brouwer RN CNN

Assessment for a Dysfunctional Access
John White, RN

Patient Satisfaction: A Key to Any Access Program
Terry F. Litchfield, M.P.A. VP, Clinical Operations RMS Lifeline

ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Prayer Warriors: A Grounded Theory Study of American Indians Receiving Hemodialysis
(Vol 34/No. 4. Expires 08/20/2009)
Joni Walton, PhD, APRN, BC, RRT
1.3 hr

Important Considerations in Iron Management and Nutritional Status in Select Hemodialysis Populations
(Vol 34/No. 4. Expires 08/20/2009)
JRosie Olivares, RN
1.5 hr

Sodium Profiling: The Key to Reducing Symptoms of Dialysis?
(Vol 34/No. 4. Expires 08/20/2009)
Paula McLaren, PgDipHigherEd, BSc (Hons),RGN; Cheri Hunter, MSc, BA (Hons) Ed, Cert Ed (Distinction), Cert Counselling, FETC, RGN, Dip Nursing (Canada)
1.5 hr

Von Hippel-Lindau Disease: An Overview
(Vol 34/No. 4. Expires 08/20/2009)
Michele Inglese, MSN, RN, CNN
1.0 hr


Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Home Hemodialysis Topics (10 talks)
Christopher Blagg, MD., Joseph Pulliam, MD., John Moran, MD., Nancy Meyer, RN, CNN., Sylvia Donato-Moore, BSN, RN, CNN., Rosa M. Marticorena, RN, BScN, DCE

New Developments in HD Technology (4 talks)
Derrick Latos, MD., James Antaki, PhD., Rita McGill, MD

Anemia: What's New, What's Old and What's on the Horizon? (5 talks)
Daniel W. Coyne, MD., Warren Shapiro, MD., Anatole Besarab, MD., Vaughn Folkert, MD., Jay Wish, MD



August 29th, 2007

Burkart  
Characteristics of the Long-Term Peritoneal Dialysis Patient   
John M. Burkart, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Burkart: Why do so few patients remain on PD after 5 or 10 years? What are the main reasons leading to technique failure? What characterizes patients who do remain on PD for the long-term? How does peritoneal transport change over time, and how is this affected by glucose load, glucose degradation products, and use of icodextrin? What are the current theories relating to AGE and inflammatory mediators in causing peritoneal membrane changes over time, including those of peritoneal sclerosis?



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part 6 of 7.    Note: Access is FREE for ASDIN members.
Slide Handouts

Drug Reactions
Aris Urbanes, MD

Venography and the Risk of Radiocontrast Nephropathy
Arif Asif, MD

Central Venous Stenosis: To Stent or Not to Stent?
Timothy Pflederer, MD

Basilic Fistulae: Is Superficialization Needed?
Kenneth Abreo, MD

Does Hemodynamic Assessment During Angioplasty Help?
Naveen Atray, MD, FASN

Peri-anastomotic Stenosis: Surgery or PTA?
Florin Gadalean, MD

Cephalic Arch Stenosis: PTA, Stent or Surgical Revision?
Sanford Altman, MD

Secondary Arteriovenous Fistulae: How to Find Candidates and When to Convert Them?
Gerald Beathard, MD, PhD, FASN

Clinical Epidemiology: Vascular Access Options and Outcomes
Pietro Ravani MD

Vascular Access Research: What Do We Need?
Anatole Besarab, MD

Non-invasive Strategies to Limit Access Stenosis
Prabir Roy-Chaudhury, MBBS, MSc, PhD, FRCP


Annual Dialysis Conference 2007
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2007)

Clinical Topics (15 talks)
Peter G. Blake, MB., William Salzer, MD., Pranay Kathuria, MD., Joanne Bargman, MD., M. R. Pete Hayden, MD., John C. Van Stone, MD., M. R. Pete Hayden, MD., Kamyar Kalantar-Zadeh, MD, PhD, MPH

Nocturnal HD: QD vs. QOD (4 talks)
Peter G. Kerr, MB, BS, PhD., Andreas Pierratos, MD., Dennis Ross, MD



August 14th, 2007

Hise  
Prospects and Challenges for a Staphylococcal Vaccine   
Michael K. Hise, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Hise: What are the requirements for a successful vaccine? How does a vaccine interact with T and B cells? What is the history behind Staphylococcal vaccine trials in dialysis patients? What did the NEJM study show? How can we explain the results? Were there promising indications of future success? What happened with the confirmatory study of StaphVax™? What are the current staphylococcal vaccines under development? What is the role of intravenous Staph. aureus immune globulin?



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part 5 of 7.    Note: Access is FREE for ASDIN members.
Slide Handouts

Access Surveillance is Useless
Jack Work, MD

Access Surveillance is Critical
Anatole Besarab, MD

Angioplasty Works for Access Stenosis
Bart Dolmatch, MD

Temporary Dialysis Catheters
Aslam Pervez, MD

Insertion of a Tunneled Hemodialysis Catheter
Alexander Yevzlin, MD

Tunneled Catheter Design and Performance
Stephen Ash, MD, FACP

Fibrin Sheath/Peri-catheter Thrombus/Right Atrial Thrombus
Aris Urbanes, MD

Antibiotic Lock Solutions and Catheter Infection
Stephen Ash, MD, FACP

Peel-away Sheath Approach is Better for Catheter Insertion
Carlos Rivera-Berm£dez, MD

Sheathless Approach is Better for Catheter Insertion
Ivan Maya, MD

Audit Sedation and Other Procedure-Related Complications
Gerald Beathard, MD, PhD, FASN


ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Last batch !!

Hypertension, Chronic Kidney Disease, and Cardiovascular Disease: Strategies to Optimize Risk Reduction - 16 talks
Toto RD, De Zeeuw D, Singh AK, Weir MR, Falkner BE, Townsend RR, Norris KC, August P, Sarnak MJ, London GM, Shlipak MG, Kramer HJ, Tuttle KR, Calhoun DA, Dworkin LD.

Plenary Session: Presidential Address, John Peters Award, Redox Reactions in Cell Signaling and Inflammation - 3 talks
DuBose TD, Giebisch GH, Freeman B

Plenary Session: Young Investigator Award. Molecular Dissection of Complex Genetic Disease Using the HapMap - 2 talks
Benzing T, Chakravarti A.

Plenary Session. Homer Smith Award. Stem Cells, Cloning, and Therapy: Promise, Problems, Reality - 2 talks
Strom TB, Jaenisch R

Target Blood Pressure in Chronic Kidney Disease - What Have Our Trials Taught Us? - 3 talks
Rahman M, Sarnak MJ, Jafar TH

Untying the Gordian Knot: ER Stress & Unfolded Protein Response in Metabolic Syndrome & the Kidney - 2 talks
Deshaies RJ, Kaufman R



July 24th, 2007

Lentino  
Alternatives to Vancomycin in the Treatment of Gram-Positive Cocci   
Joseph R. Lentino, MD, PhD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Lentino: At least 7 new antibiotics (not all approved by the FDA) are available for certain indications in patients infected with VRE or MRSA who either fail vancomycin treatment or need alternative treatment: Quinupristin/dalfopristin, linezolid, daptomycin, tigeycline, dalbavancin, oritavancin, and teicoplanin. What are potential indications for each of these? What particular resistant organisms is each one good against? Bad against? Which are not indicated for treatment of pneumonia? What are their peculiar side effects?



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part 4 of 7..    Note: Access is FREE for ASDIN members.
Slide Handouts

Ultrasound Guidance for Renal Biopsy by Nephrologists
Juan Pablo Herrera Felix, MD

Renal Ultrasonography by Nephrologists
Charles O'Neill, MD

Peritoneal Catheters: Insertion Techniques by Nephrologists
Kenneth Abreo, MD

Pathophysiology, Clinical Features and Differential Diagnosis
Arif Asif, MD

Diagnostic Evaluation of Hand Ischemia
Bhagwan Bhimani, MD

Mathematics of DRIL
Bernard Gerstman, PhD

Percutaneous Approach to Hand Ischemia
Antoine Samaha, MD

Surgical Approach to Hand Ischemia
Pierre Bourquelot, MD

Heart Failure and Dialysis Access
Haimanot Wasse, MD, MPH

Surgical Inflow Reduction for High Output Fistulae
Eric Chemla, BSc, FRCS

Percutaneous Inflow Reduction for High Output Fistulae
Gregg Miller, MD


ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis
(Vol 34/No. 3. Expires 06/20/2009)
Karen Hamilton-Persaud, BSN, RN; Loretta D. Ezell, BSN, RN, CNN; Joyce G. Macklin, RN, CNN
1.4 hr

A Descriptive Study of Individuals with Membranoproliferative Glomerulonephritis
(Vol 34/No. 3. Expires 06/20/2009)
Der-Fa Lu, PhD, RN; Ann Marie McCarthy, PhD, RN, FAAN; Lynne D. Lanning, BSN, RN, JD; Connie Delaney, PhD, RN, FAAN; Craig Porter, MD
1.5 hr

The Relationships Between Nurses'Perceptions of the Hemodialysis Unit Work Environment and Nurse Turnover, Patient Satisfaction, and Hospitalizations
(Vol 34/No. 3. Expires 06/20/2009)

Jane K. Gardner, DNP, RN; Charlotte Thomas-Hawkins, PhD, RN; Louis Fogg, PhD, RN; Carolyn E. Latham, MSN, MBA, RN, CNN




ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Essential Concepts of Diagnostic and Interventional Nephrology (21 talks)
Pflederer TA, Miller PL, Lewis JL, Beathard GA, Abreo KD, Miller KA, Work J, Saad TF, Neill WC, Mishler RE, Hoggard JG, Samaha AL, Urbanes AQ, Brouwer DJ, Francisco LL, Krivitski NM, Besarab A, Asif A.

Kidney Disease Research within the NIH Roadmap: Strategies for the Future (1 talk)
Zerhouni E

Advances in Research Conference: Stem Cells in Organ Maintenance and Repair (17 talks)
Cantley LG, Krause D, Kaushansky K, Fuller MT, Li L, Blanpain C, Rao M, Rosenberg ME, Yoder MC, Prockop DJ, Singla DK, Horwitz E, Grompe M, Crooks GM, Bonventre JV, Stappenback T, Lavik, E.

Pharmacoeconomics in Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD): Getting Your Money's Worth (3 talks)
Provenzano R, Nissenson AR, Manns BJ



July 8th, 2007

Allon  
Overview of Catheter Lock Solutions   
Michael Allon, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Allon: How has fistula first affected the rate of catheter insertions? How do we handle an infected catheter - what are the options? What are the causative organisms? What should coverage be? How can catheter lock solutions be used to help manage an infected catheter? What was the success rate at University of Alabama Birmingham? At other institutions? How easy is it to use catheter lock solutions? What is the protocol? When should the catheter absolutely be removed?



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part Three.    Note: Access is FREE for ASDIN members.
Slide Handouts

Tunneled Catheter Breakage During Removal Procedure
Aslam Pervez, MD

Advancement of IJ Catheter in the IVC
George Nassar, MD

Balloon Detachment During Angioplasty
Carlos Alberto Mercado, MD

Stent Floating
Theodore Saad, MD

Catheter Insertion in Bachiocephalic Vein
Abigail Falk, MD

Emerging Role of Ultrasound in Vascular Access Care
Linda Francisco, MD


ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Critical Care Nephrology: 2006 Update (20 talks!)
Murray PT, Matthay M, Chawla LS, Tolwani AJ, Corwin HL, Davenport A, Mehta RL, Star RA, Palevsky PM, Paganini EP, Marshall MR, Goldstein S, Dowling TC, Goldfarb DS.

Critically Approaching the Literature: Applying the Principles of Epidemiology and Biostatistics
Thadhani RI, Feldman HI, Klag MJ, Wanner C, Greene TH, Garg A, Parekh RS, Lo B, Holdaas H, Jardine AG, Powe NR, Bowden DW, Johansen KL

Plenary Session: Narins Award, Scribner Award, Nanotechnology in Drug Delivery and Tissue Engineering
Saltzman WM

President's Special Symposium: Disasters and Nephrology: Lessons from Katrina
Kopp JB, Cohen AJ, Navar LG

Prevention of Vascular Stenosis/Thrombosis
Schwab SJ, Dember LM, Allon M, Jiang C, Myazaki M



June 9th, 2007

Parving  

Bakris  
 
Are ACE-I and ARBs Essential For Renoprotection? Debate   
Hans Henrik Parving, MD, and Geroge Bakris, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2006.)
Parving: Four studies have questioned the renoprotective effects of ACE inhibitors. What are their potential weaknesses? What are the different stages of renoprotection, and which trials studied which stage? Should all type 1 diabetic patients receive ACE inhibitors? What did BENEDICT, IRMA2, RENAAL, and IDNT show? What do observational data of Danish patients show in terms of median survival time of type 1 diabetics treated with ACE inhibitors? Bakris: To what extent is microalbuminuria a cardiovascular marker in addition to being a renal progression marker? How important is the level of blood pressure control? Do ACE-I or ARBs affect eGFR, or only proteinuria? What did we learn from the ABCD trial, form ALLHAT, and from other similar studies?



ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part Two.    Note: Access is FREE for ASDIN members.
Slide Handouts

Vein Obliteration and Embolization Techniques
Jan Bijan Tawakol, MD

Point/Counterpoint Fistula Thrombectomy: Use of Devices
Abigail Falk, MD

Fistula Thrombectomy: TPA and Aspiration of Clot
Donald Schon, MD, FACP

Thrombectomy of an AVG: What Technique to Use?
Jack Work, MD

Fistula First
Jeffrey Sands, MD

Fistula Worst
Antoine Samaha, MD

Grafts are Better than Transposed Fistulae
Frederick Schild, MD, FACS

Arterial Embolization During Thrombectomy
Abigail Falk, MD

Arterial Intimal Tear
Timothy Pflederer, MD

Percutaneous Approach to Hand Ischemia
Antoine Samaha, MD


ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Are Calcineurin Inhibitors Still Useful in Transplantation?
Hricik DE, Vincenti FG, Meier-Kriesche H

Morbidity and Mortality in CKD: Evidence-based Choices in the Treatment of SHPT
Thadhani RI, Kalantar-Zadeh K, Salusky IB

Death by Design: Autophagy in Health and Disease
Rubinsztein D, Cuervo AM, Franch HA

Deriving Clinical Pearls from Transcriptional Studies in Renal Development and Disease
Libermann T, Smith MS, Koop K

Does Fetal Programming Influence Adult Hypertension?
Ross MG, Nuyt AM, Alexander BT, Longo M

Molecules in Motion: Cellular Stop/Go Signs
Wandinger-Ness A, Maxfield F, Pfeffer S, Benzing T

Acute Kidney Injury
Mehta RL, Devarajan P, Chawla LS, Tumlin JA

Lupus Nephritis
Jennette JC, Ginzler EM, Radhakrishnan J, Contreras G

Medical Complications After Kidney Transplantation: What the General Nephrologist Must Know
Djamali A, Kasiske BL, Hricik DE, Coco M

Obesity and the Kidney
Beddhu S, Kalantar-Zadeh K, Abbott KC, Lieske JC

Basic Science Evening Symposium: New Imaging Technologies: From Cells to Mice to Man
Bell DP

Cell/Matrix Interactions and Downstream Signaling in Development and Disease
Wu C, Zent R, Ronco PM

Fibroblastic Growth Factors in Development and Disease
Perantoni AO, Grose R

Lipid Rafts and Cell Function
Shayman JA, Pike LJ, Insel P, Levi M



May 24th, 2007

Wish  

McClellan  

Lafayette  
 
Early Anemia Management: Incorporating New Evidence Into Appropriate Treatment Strategies for Chronic Kidney Disease   
Jay B. Wish, MD; William M. McClellan, Jr, MD; Richard A Lafayette, MD.
(Based on an RPA Satellite Symposium organized by Scepter™; March, 2007.)
Wish: Framing the issues. Consequences of anemia. Anemia as a mortality multiplier. Importance of RCTs. Current state of K/DOQI guidelines and their anticipated revision. McClellan: Impact on Patient Outcomes and Health Care Costs. What is the prevalence of anemia in CKD patients? What is the economic burden of untreated anemia in elderly patients with CKD? What do the quality of life studies show? What do observational studies show in terms of anemia, CVD risk, and risk of progression? Wish (again): What is the rationale for early anemia treatment? How have the results from CHOIR and CREATE affected our target Hb levels? How do we define anemia? What are the K/DOQI 2006 opinions? What did a meta-analysis of RCTs prior to CHOIR and CREATE show? What did CHOIR show? What did CREATE show? What do the now RCTs mean? Lafayette: How often should we dose ESAs to treat anemia? How do the different available ESAs differ in this regard? What are the results with less frequent dosing of epoetin alfa? Darbepoetin alfa? What did the POWER, RAPID, and PROMPT studies show? How much do ESAs cost in an ambulatory setting? In a hospital setting? What are cost comparisons between darbepoetin and epoetin alfa? How do we minimize cycling when using the new, lower Hb targets?



Gutman  

Casey  

Maddux  

Kliger  

Golper  

Mecum  
Improving Efficiency in the Nephrologist's Office. Part Two of Two.   
Flash - slide/audio and MP3/WMA audio
(RPA Annual Meeting, March, 2007.)

This is free to RPA members. Please look at the RPA members only section on the RPA website for access instructions.

The Full Court Press on Dialysis Facility Medical Directors
Robert A. Gutman, MD

The Center Position: Federal Regulations: Deciphering the law
Mary Teresa Casey, RD, LD

The Nephrologist As Medical Director A Clash of Cultures or Evolving History?
Franklin W. Maddux, M.D. F.A.C.P.

Point Guard Value: Quality Improvement and Oversight
Alan Kliger, MD

Integrating Advanced Practice Nurses and Physician Assistants Into Nephrology Practice: When Is The Right Time?
Thomas A. Golper, MD, FACP, FASN

Using Benchmarking to Improve Practice Efficiency
Suzanne C. Mecum, CPA, FACMPE


ASDIN
 
3rd Annual Meeting. American Society of Diagnostic and Interventional Nephrology. April, 2007. Part One.    Note: Access is FREE for ASDIN members.
Slide Handouts

Basic Vascular Anatomy and its Application: The Arterial Circulation, Superficial and Deep Venous Systems
Peter Miller, MD

Preservation of Veins in CKD
Theodore Saad, MD

Arteriovenous Fistula Creation
Rick Mishler, MD, FACP

Physical Examination of an Arteriovenous Access
Gerald Beathard, MD, PhD, FASN

Mechanisms of Early Fistula Failure
Prabir Roy-Chaudhury, MBBS, MSc, PhD, FRCP

Diagnosis and Timing of Intervention in Early Failure
Aris Urbanes, MD

Percutaneous Approach to Salvage Fistulae with Early Failure
George Nassar, MD

Surgical Approach to Salvage Fistulae with Early Failure
Surendra Shenoy, MD

Endovascular Stents and Stent Grafts
Bart Dolmatch, MD


ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

The Adolescent Patient: A Transition from Childhood to Adulthood
Goodman RS, Antonelli RC, Ferris ME, Gipson DS, and Goldstein S

Estimating GFR - Quo Vadis?
Levey AS, Rule AD, Coresh J, Hostetter TH

Genetic Pathways in Cystic Kidney Disease Pathogenesis
Pei YP, Badano JL, Weimbs T

Going for the Gold: Achieving Clinical Tolerance
Norman DJ, Knechtle J, Newell KA, Sayegh MH

Mechanisms Underlying Exercise Attenuation of Cardiovascular Risk
Mora S, Libonati JR, Adams V

Molecular Traffic Jams: Cargo No-Go?
Deen PMT, Gissen P, Danpure CJ, Caplan MJ

New Techniques with Conventional In-Center Hemodialysis
Manns BJ, Ward RA, Jaber BL, Kooman J

Novel Mechanisms Regulating Vascular Function
Garvin JL, Eckhart A, Gallagher PE, Terzi F

Perspectives on Clinical Science in Acute Kidney Injury
Parikh C, Ikizler TA, Paganini EP

Role of Vitamin D as a Survival Factor
Brown AJ, Thadhani RI, Hollis BW, Dusso AS

The Glomerulus and Beyond: Albumin Barriers and Carriers
Rippe B, Shaw A, Christensen EI

TRP Channels and Tubular Function
Schilling W, Bindels RJ, Cohen DM, Dow J



May 7th, 2007

Provenzano  

Nissenson  

Blaser  

Clancy  

Mazak  

Sennett  

Paganini  

Goldman  
 
Improving Efficiency in the Nephrologist's Office. Part One of Two.   
Flash - slide/audio and MP3/WMA audio
(RPA Annual Meeting, March, 2007.)

This is free to RPA members. Please look at the RPA members only section on the RPA website for access instructions.
RPA: Year in Review, Recognition Awards
Robert Provenzano, MD

FDA Public Health Advisory Erythropoiesis-Stimulating Agents (ESAs)
Allen Nissenson, MD

RPA's Advocacy Agenda
Robert Blaser, MD

Louis Diamond Lecture: Leading the Way to High Quality Care
Carolyn M. Clancy, MD

Creating Governance in Your Practice: An Essential Element of Change
Mark E. Mazak

Maximizing The Value of Your Practice Through Maintenance of Certification
Cary S. Sennett, MD, PhD

RPA's Physician Payment Survey Results
Emil P. Paganini, MD

Is My Practice Prepared? Measuring Performance with P4P Mind
Richard Goldman, MD


RRI  
RRI Ninth International Conference on Dialysis, January, 2007. Part Four.   
Flash slide/audio; WMV portable device slide/audio; WMA/MP3 audio
Debate: Observational Research Generates Many New Insights into Dialysis
Friedrich K. Port, MD, MS

Debate: Hemodialysis Adequacy: Observational Research Results are Often Misleading!
John T. Daugirdas, MD

Debate: The New K/DOQI Guidelines Provide Safe and Adequate Standards
Joanne M. Bargman MD FRCPC

Debate: The 2006 K/DOQI Guidelines for Peritoneal Dialysis Adequacy Are Not Adequate
James Winchester, MD

Debate: The Treatment Time and Ultrafiltration Rate Are More Important in Dialysis Prescription than Small Molecule Clearance
Zbylut J. Twardowski, MD, PhD, FACP

Debate: The Treatment Time and Ultrafiltration Debate
Frank Gotch, MD

Fighting Sudden Death in Dialysis Patients: A Cardiologist's Perspective
Charles A. Herzog, MD

Emphasizing kidney donation: the long-term outcome of living donors
Amit X. Garg MD, MA (Education), FRCPC, FACP, PhD


ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Advances in Understanding Thrombotic Microangiopathies
Motto DG, Asahara T, Ponticelli C.

Effects of Inflammation on Kidney Function Before, During, and After Dialysis
Wetmore JB, Stenvinkel P, Hung AM, Schindler R.

Epithelial-Mesenchymal Transition in Fibrosis: Whither the Controversy?
Morrissey JJ, Liu Y, Lovett DH, Barnes JL, Kriz W.

Friend or Foe? Complement Regulation of Immune Cell Function
Heeger PS, Quigg RJ, Morgan BP.

Genetic Tools to Study Renal Function and Development
Quaggin SE, Igarashi P, Lieberman J.

Immune Monitoring in the 21st Century
Reinsmoen N, Brennan DC, Rush DN, Kirk AD

Mechanisms of Vascular Calcification
Towler DA, Shanahan CM, Hruska KA.

Models and Mediators of Tissue Repair
Redd M, Serhan CN, Hirschberg RR.

New and Updated KDOQI Guidelines
Levin A, Van Wyck DB, Nelson RG, Depner TA, Besarab A.

Of Branches and Cues: The Universal Language of Nephro-Vascular Interactions During Kidney Morphogenesis and Disease
Ghabrial A, Kreidberj JA, Tufro A.

Signaling Pathways in Cystic Kidney Disease - Insights from Evolutionary Developmental Biology
Kaufman T, Pontoglio M, Yoder BK, Bell PD.



April 21st, 2007

RRI  
RRI Ninth International Conference on Dialysis, January, 2007. Part Three.   
Does size matter? How new studies on body composition can improve understanding of outcomes in dialysis patients
Peter Kotanko, MD

Biofilms are everywhere: What is its relevance for CKD, PD and HD?
Steven Offenbacher, DDS, PhD, MMSc

Changing the fate of diabetics in the dialysis unit
Behrooz Broumand, MD, FACP

Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease: What Will They Do For Patient Management?
Robert G. Nelson, MD, PhD

Does genetics explain the international differences in dialysis mortality?
Tetsuo Shoji, MD, PhD

Nanotechnology and Dialysis: Now, ten years, or never?
William H. Fissell, MD

A Practical Approach to Pharmacokinetics in CKD Patients
Bruce A. Mueller, Pharm.D, FCCP

Fistula First - Catheter Out! Barriers and Solutions
Jeffrey J. Sands, MD

Vitamin C Neglect in HD: Sailing Between Scylla and Charybdis
Garry Handelman, PhD




Malluche  

Sprague  

Andress  
 
Bone and Mineral Metabolism in CKD: Medical Crossfire (video archive)   
Hartmut H. Malluche, MD, Stuart M. Sprague, DO, and Dennis L. Andress, MD (Moderator: Peter Salgo, MD).
(ASN Renal Week, Official Symposium. November, 2006.)
Malluche: Case of a patient with calciphylaxis. How do we approach this case? What is the changing picture of metabolic bone disease in CKD during the past 5-10 years? How is bone turnover linked to vascular calcification? How good is PTH as a method of diagnosing bone turnover? What effects do lanthanum-containing Pi binders have on serum Pi, Ca, and PTH? On bone turnover markers? Sprague: Case of a young male with periarticular shoulder calcification. How does PTH associate with death risk in CKD patients? How do calcification types differ, and what is the relationship to mortality with each type in CKD? What are factors affecting vascular calcification? How do calcium-containing binders vs. non-calcium containing binders affect vascular calcification? What did the DCOR study show? DOPPS? Is there an effect on mortality? Andress: Vitamin D has a primary role in control of PTH. What other organs have the Vitamin D receptor (VDR)? How do different activators of VDR differ? What do studies show regarding mortality vs. use of VDR activators? What effect do VDR activators have on bone mineral density?

Then we have discussion, peer exchange, and more discussion, all archived from the original Medical Crossfire video. All discussions have been transcribed and separated out for ease of use.



ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Chronic Kidney Disease and Cardiovascular Disease: A Case Presentation
(Vol 34/No. 2. Expires 04/20/2009)
Patricia B. McCarley, MSN, RN, NP, CNN; Patricia B. Salai, MSN, RN, CRNP, CNN
1.5 hr

Assessment of the Impact of Weekly Versus Monthly Erythropoiesis Stimulating Protein Therapy on Patients with CKD and Their Families
(Vol 34/No. 2. Expires 04/20/2009)
Denise Globe, PhD; Deborah Glidden, MSN, ARNP-C, CNN; Joachim Hertel, MD, FACP; Joele Thomas, BSN, RN; Michele Ackerman, ASN, RN; Felicia Chidolue, MSN, RN, FNP-C; Bianca Blanco, BSN, RN; Annette Borden, MA; Thomas F. Goss, PharmD; Xiao Xu, PhD, RN; Reshma Kewalramani, MD
1.5 hr

Impact of an Anemia Clinic on Emergency Room Visits and Hospitalizations in Patients with Anemia of CKD Pre-Dialysis
(Vol 34/No. 2. Expires 04/20/2009)
Robert M. Perkins, MD; Stephen Olson, MD; Janice Hansen, RN; Joseph Lee, DO; Kevin Stiles, MD; Christopher Lebrun, MD
1.4 hr

Focal Segmental Glomerulosclerosis: A Case Study with Review of Pathophysiology
(Vol 34/No. 2. Expires 04/20/2009)
Anndee M. Glick, MPH, MBA, BSN, RN
1.4 hr




ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Literature Review - The Year in Nephrology: Transplantation and Peritoneal Dialysis Moderators
Halloran PF, Khanna R

Update on Diabetes and the Kidney
Wolf GB, Ziyadeh FN, Schena FP, Freedman BI

Basic Science Evening Symposium
Chakravarti A

Radiocontrast Nephropathy: An Update
Goldfarb S, Prasad PV, Palevsky PM

Dealing with Fistula Failure
Pflederer TA, Mishler RE, Beathard GA, Asif A

Home Dialysis and Intensive Dialysis Therapies
Chan CT, Pierratos A, Lockridge RS, Lindsay RM

Nephrology Quiz & Questionnaire
Falk RJ, Josephson MA, Hamm LL, Adler SG, Singh AK

New Therapies for Old Diseases
Glassock RJ, Dember LM, Jayne DRW, Hogg RJ, Nachman PH



April 7th, 2007

RRI  
RRI Ninth International Conference on Dialysis, January, 2007. Part Two.   
Understanding the Finances of the Individual Dialysis Facility
Peter DeOreo , MD, FACP

How To Survive The Hemodialysis Unit Survey
Terry Sullivan, RN, MS

The Survey of a Hemodialysis Unit as seen by the Federal Government
Judith Kari, MSSW

What should the target Hgb Level be?
Steven Fishbane, MD

Impact of the Change in CMS Billing Rules for Erythropoietin on Hemoglobin Outcomes in Dialysis Patients
Norma J. Ofsthun, PhD

A Kinetic Model of Calcium Mass Balance During Dialysis Therapy
Frank Gotch, MD

Guidelines for Practice Guidelines
Richard Amerling, MD

Coronary Artery Calcifications - A Critical Assessment of Imaging Techniques
Alexander Lembcke, MD




Schrier  

Greenberg  
Fluid Dysregulation: Disturbances and Management   
Robert W. Schrier, MD, and Arthur Greenberg, MD.
(ASN Renal Week, Official Symposium. November, 2006.) Schrier: Who were the key players in discovering the osmotic and non-osmotic pathways of vasopressin release, the structure of AVP, the V2 receptor, the aquaporin channel, and the first orally- acting nonpeptide V2-receptor antagonist? How does vasopressin regulate aquaporin expression and trafficking in the nephron? Which mutations cause diabetes insipidus? What is the mechanism of the urinary concentrating and free water excretion defects in primary polydypsia? In hypothyroidism? In glucocorticoid deficiency? In mineralocorticoid deficiency? Pregnancy? How is AQP2 involved in all of these conditions? How is AQP2 involved in acquired, nephrogenic diabetes insipidus? How are vasopressin and AQP2 involved in the hyponatremia and water excretion deficits associated with heart failure and liver cirrhosis? What effect do V2-receptor antagonists have in these conditions, and what are their effects on AQP2? Greenberg: What are the vasopressin receptor subtypes, where does each act? Which V-receptor antagonists are specific for V2? What effects do vasopressin (VR) antagonists have treating the hyponatremia and free water excretion deficits associated with SIADH, congestive heart failure, and cirrhosis? What did the SALT-1 and SALT-2 trials show? What are the risks associated with rapid correction of hyponatremia? What are safe correction rates? How do VR-antagonists fit into this? What is an overall diagnostic approach to hyponatremia?



ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Models and Mediators of Tissue Repair
Redd M, Serhan CN, Hirschberg RR

New and Updated KDOQI Guidelines
Levin A, Van Wyck DB, Nelson RB, Depner TA, Besarab A

Idiopathic Membranous Nephropathy
Cattran DC, Wetzels JF, Alexopoulos E, Fervenza FC

Advances in Understanding Thrombotic Microangiopathies
Motto DG, Asahara T, Ponticelli C

Effects of Inflammation on Kidney Function Before, During, and After Dialysis
Wetmore JB, Stenvinkel P, Hung AM, Schindler R

Epithelial-Mesenchymal Transition in Fibrosis: Whither the Controversy?
Morrissey JJ, Liu Y, Lovett DH, Barnes JL, Kriz W

Friend or Foe? Complement Regulation of Immune Cell Function
Heeger PS, Quigg RJ, Morgan BP

Genetic Tools to Study Renal Function and Development
Quaggin SE, Igarashi P, Lieberman J

Immune Monitoring in the 21st Century
Reinsmoen N, Brennan DC, Rush DN, Kirk AD

Mechanisms of Vascular Calcification
Towler DA, Shanahan CM, Hruska KA



March 27th, 2007

RRI  
RRI Ninth International Conference on Dialysis, January, 2007. Part One   
How Dialysis Machines Work
Thomas Roy, PhD

Water quality and dialysis fluid composition
Nicholas Hoenich, MD

Difficulties in Providing Adequate Dialysis
Jose Diaz-Buxo, MD

What is Now Expected from Medical Directors? 2007
Robert Provenzano, MD

Practical Approaches to Management of Hyperphosphatemia
Martin K. Kuhlmann, MD

The Management of Dialysis Units The European Perspective
Andrea Stopper, MD




Kaysen  

Sarnak  

Stenvinkel  
Inflammation in CKD: Biomarkers, Morbidity and Therapy   
George Kaysen, MD, PhD; Mark Sarnak, MD; Peter Stenvinkel, MD, PhD.
(ASN Renal Week, Official Symposium. November, 2006.) Kaysen: Biomarkers - To what extent does CRP give additional prognostic info apart from traditional risk factors like LDL cholesterol and in ESRD patients, low serum albumin? Are there other, better markers? Especially, IL-6? How does EPO/Hct ratio correlate with inflammatory markers and survival? Sarnak: Is CRP higher in CKD patients or isn't it? Do elevated levels in pre-ESRD patients predict progression or incident hypertension? To what extent to inflammatory markers perdict cardiovascular disease outcomes in CKD patients? Stenvinkel: Eating nuts, soy, or fish: do such dietary changes impact on inflammatory markers or outcomes? What is the effect of statins on CRP and other inflammatory markers in CKD? ACE inhibitors? What is the alpha vs. gamma tocopherol story? How do heparin, N-acetylcysteine, sevelamer and PPAR-gamma activators impact on inflammatory markers? Are there outcomes studies showing that lowering CRP in CKD is of clinical benefit?



Gaston  

Brennan  
Managing CMV Infections in Transplantation   
Robert S. Gaston, MD; Danniel C. Brennan, MD
(ASN Renal Week, Official Symposium. November, 2006.) Gaston: How has our view of CMV evolved from 1964 to the present? What are the direct vs. indirect effects of CMV infection in transplant recipients? What is the impact of CMV infection or CMV prophylaxis on acute rejection? On long-term allograft function? On metabolic syndrome and post-transplant diabetes? On secondary viral and bacterial infection? On post-transplant lymphoproliferative disorder? Brennan: To what extent does CMV prophylaxis prevent vs. delay post-transplant CMV disease? What is a pre-emptive vs. a prophylactic strategy? Is a pre-emptive strategy better? Is it cheaper?



ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Sudden Death in Hemodialysis Patients: Towards Prevention
Chavers BM, Herzog CA, McCullough PA, Hanly P

Should We Change Our Organ Allocation Policies for Kidney Transplantation?
Matas AJ, Port FK, Tomlanovich SJ, Becker BN

Highlights from the 2006 Meeting of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)
Kimmel PL, Coppo R, Wanner C, Lameire NH, Grinyo JMB

Drugs and the Kidney
Roth D, Norris KC, Perazella MA, Foley RN, DeBroe ME

Basic Science for Clinical Nephrologists - Mechanisms of Viral Injury to the Kidney
Berns JS, Bruggeman LA, Gharavi AB, Alpers CE.

Literature Review - The Year in Nephrology: Osteodystrophy and Vascular Calcification, and Chronic Kidney Disease: Cardiovascular Complications
Llach F, Levin A.

The CKD that Follows Renal Transplantation: How to Best Manage these Patients
Danovitch GM, Chandraker A, Kupin WL

Update on Focal and Segmental Glomerulosclerosis
Schnaper HW, Holzman LB, Appel GB



March 16th, 2007

Berl  

Stokes  
Disorders of Sodium Metabolism: Case Presentations   
Tomas Berl, MD and John Stokes, MD
(ASN Board Review Course, 2006).
Drs. Berls and Stokes present their interesting patients: (1) A woman with flank pain on heparin with hypotension and hyponatremia; (2) a middle-aged male with nephrotic syndrome and severe edema (how would you manage his refractory edema?); (3) Hyponatremia and elevated urinary sodium excretion after subarachnoid hemorrhage. What equation does one use to correct sodium in patients with hyponatremia? (4) Woman with progressive edema and dyspnea. Why does she have edema? (5) Woman with chronic diuretic use and now diuretic-dependent edema without obvious cause.




Chandraker  

Kupin  
The CKD that Follows Renal Transplantation: How to Best Manage these Patients?   
Anil Chandraker, MD; Warren Kupin, MD; Moderator: Gabe Danovitch, MD.
(ASN Renal Week Official Symposium, 2006).
Chandraker: The long-term survival of allografts has not improved. What is the pathogenesis of chronic allograft nephropathy (CAN) and dysfunction (CAD)? How is the changing (decreasing) quality of organ donors (brain-dead donors, expanded criteria donors) affecting this? What alloantigen-dependent factors affect CAD? How are HLA antibodies involved? What are the main alloantigen- independent factors? How can we mitigate these? How does hyperlipidemia impact on CAD? What are the mechanisms? How is CKD after transplant different from CKD in predialysis patients? Kupin: What is the prevalence of stage 3 and 4 CKD after kidney transplant? After transplantation of other organs? What are the new KDIGO staging recommendations? How should we treat hypertension after transplant? Which CCBs? Are ACE-Is and ARBs particularly beneficial? How prevalent is anemia post-transplant? Are there any particular immunologic concerns related to EPO use? How aggressively should we manage lipids? How do immunosuppressive drugs impact on this? What is the latest info on how best to manage post-transplant bone disease (osteoporosis, hyperparathyroidism)?



ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Chronic Kidney Disease and Cardiovascular Disease: Pathophysiologic Links
(Vol 34/No. 1. Expires 02/20/2009)
LaVonne Burrows, APRN, BC, CNN; Robert Muller, MSN, RN, FNP-C
1.5 hr

Flash Pulmonary Edema in Patients with Chronic Kidney Disease and End Stage Renal Disease
(Vol 34/No. 1. Expires 02/20/2009)
Carol M. Headley, DNSc, RN, CNN; Barry M. Wall, MD
1.5 hr

The Multidimensional Characteristics of Symptoms Reported by Patients on Hemodialysis
(Vol 34/No. 1. Expires 02/20/2009)
Anita Jablonski, PhD, RN
1.5 hr

Feasibility of Using a Personal Digital Assistant to Self-Monitor Diet and Fluid Intake: A Pilot Study
(Vol 34/No. 1. Expires 02/20/2009)
Janet L. Welch, DNS, RN; Shannon Dowell, MSN, RN; Cynthia S. Johnson, MA
1.5 hr




ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Debates in Renal Failure: Renoprotection: ACEs and ARBs Do More Than Just Lower Blood Pressure
Linas SL, Parving H, Bakris GL

Staphylococcal Infection in Dialysis Patients
Shemin DG, Piraino BM, Allon M, Lok CI, Lentino JR, Hise MK

Hypertension in Chronic Kidney Disease (CKD) Populations
Kupin WL, Rossing K, Townsend RR

CKD Management: Pathophysiologic and Clinical Perspectives
Bushinsky DA, Kumar R, Block GA

Cardiovascular Disease and the Morbidity and Mortality in ESRD: Role of Vitamin D and Bone
Slatopolsky E, Wolf MS, Hruska KA

Vitamin D Deficiency and Early CKD
Sprague SM, Levin A, Ho LT



February 27th, 2007

Olson  
Transplant Biopsy   
Jean Olson, MD
(ASN Board Review Course, 2006).
Olson: Biopsy interpretation depends on circumstances and time frame. First two weeks, first 6 months, and months to years after transplant, one tends to think of different causalities. What does acute humoral rejection look like? What about acute rejection? How do we use the Banff and CCTT classifications? What about ATN post-transplant? How do we identify calcineurin inhibitor nephrotoxicity? Renal toxicity due to OKT3? Rapamycin? IVIG? Acute interstitial nephritis due to antibiotics? How do we approach polyomavirus nephropathy? What are the findings we can expect in biopsies taken months to years after transplant? What characterizes CAN? Recurrent disease, esp. FSGS? Diabets? Anti-GBM in Alport syndrome? Post-transplant lymphoproliferative disorder?




Nissenson  

Coyne  
The New KDOQI Guidelines for Anemia, a Debate: Should the Upper Hgb Limit be 12 or 13 g/dL?   
Allen Nissenson, MD; Daniel Coyne, MD; Moderator: Brian Pereira, MD.
(ASN Renal Week Official Symposium, 2006).
Nissenson: What should the lower Hgb limit be? What do the May 2006 KDOQI guidelines recommend? What do the CPRs recommend regarding an upper limit? What do CARI, the Canadians, and the Europeans recommend? Which clinical outcome may continue to improve at higher Hgb levels? What might be the benefits of raising the upper limit to 13? What would be the potential risks? What did the Besarab and Parfrey RCTs show? What parts of CREATE and CHOIR are relevant to the debate? Coyne: Is a target between 11 and 12 too narrow? What is the evidence that an upper level of > 13 may be associated with harm? Is there evidence that QOL is benefited at a target of 12-13 vs. a target of 11-12?



Pharmacist CE

Lecture Free
Free CE

Hudson  
Iron-Deficiency Anemia in Various Patient Populations (target audience: Pharmacists)   
Joanna Hudson, PharmD, BCPS, FASN
(Pharmacist CE. Medical Education Resources. February, 2007.)
Hudson: What are signs and symptoms of anemia? What is the economic impact of anemia? What are the basics of erythropoiesis in CKD patients? How does functional iron deficiency arise? How do we measure iron deficiency? What are limitations of the TSAT and serum ferritin? What is the pharmacokinetics of IV iron compounds? What are the label-approved indications? What are their safety profiles? What effect does iron therapy have on ESA requirements? What are the relevant pharmacoeconomic considerations?



ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Long Term Survival in Peritoneal Dialysis (PD) Patients
Flessner MF, Krediet RT, Burkart JM, Mehrotra R

Debates in Renal Failure: Calcimimetics: Are They Effective Treatment for Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease (CKD)?
Goodman WB vs. Coyne DW (Moderator: Goldfarb S)

Viral Diseases and the Kidney: A Critical Update
Kopp JB, Brennan DC, Johnson RJ

Recurrent/Systemic Diseases in Transplantation
Bolton WK, Hariharan S, Roberts ISD, Samaniego-Picota MD

Primary Care in Nephrology
Ende J, Fosknocht KM, Paauw DS, Kreisberg RA, Tuttle KR



February 7th, 2007

Goodman  
Calcimimetics: Monotherapy for Secondary Hyperparathyroidism?   
(ASN Board Review Course, 2006).
Goodman: What is the conventional approach for managing secondary hyperparathyroidism, involving control of phosphate and use of vitamin D? To what extent does the conventional approach fail to achieve KDOQI Ca, Pi, and PTH targets? What is the calcium-sensing receptor, how to its allosteric activators work, and how does this interact with the physiology of the parathyroid cell? What effects does cinacalcet have on serum Ca, Pi, and PTH, and how is this modulated by usage of vitamin D and degree of hyperparathyroidism? When might we use cinacalcet in patients already on vitamin D? When might we use it as monotherapy? What are potential pitfalls in use of cinacalcet? What is a rational algorithm for its use?




Falk  

Appel  
Lupus Nephritis: Defining and Treating Renal Flares   
Ronald J. Falk, MD; Gerald B. Appel, MD.
(ASN Renal Week Official Symposium, 2006).
Falk: What are the current views regarding pathogenesis of SLE? What genetic predispositions have been identified? What potentially could cause a relapse? How do we define remission in lupus, and how do we define a relapse? What have been definitions given in the literature? What are serologic and urinary clues to relapse? How do we distinguish between relapse and smouldering disease? Appel: What did the early NIH trials tell us about the best lupus regimens in terms of relapse? What regimen did the Euro-lupus trial use, and what did they find regarding relapses? What did we learn from studies recently published in the New England Journal of Medicine by Contreras et al, and by Ginzler et al? What is my personal approach to treating lupus flares?



ASN Renal Week 2006
now in MP3
AUDIOFILE LIST (ASN Renal Week 2006)

Managing CKD: Key Therapeutic Issues
Townsend R, Bakris G

Advances in the Management of Secondary Hyperparathyroidism (SHPT)
Chertow GM, Drueke TB, Llach F, Moe SM

Coronary Artery Disease (CAD) in CKD: Updating the Pathophysiology and Management
Kimmel PL (moderator), Budoff MJ, Quinibi WY, McCullough PA

KDIGO - What is New
Lameire NH, Levey AS, Jadoul NY, Roth D

Clinical Application of Bone Biopsy
Schwartz E, Moe S, Clarke B, Ott S, Hruska K, Miller P, Salusky I, Malluche H, Gal-Moscovici A, Sprague S, Schwartz E



January 23rd, 2007

Townsend  
Secondary Hypertension, including Chronic Kidney Disease   
(ASN Board Review Course, 2006). Townsend: Renin system activation, mineralocorticoid excess states, pheo, aortic coarctation, and primary renal disease are the main types. What is the best means to diagnose renovascular HTN? What are less common types of RV HTN? How do we approach low renin, high aldo HTN? What are diagnostic criteria (aldo/renin ratios, urinary aldos, etc.), and what are the treatment options besides surgery? How do we approach Cushing's, pheo, and hyper- and hypothyroidism and HTN? What are the main genetic disorders? Liddle, GRH, activating MR receptor mutations, and 11-beta-hydroxysteroid dehydrogenase? What is Gordon's syndrome? What are the main drug-induced causes, including anti-angiogenesis agents? What's new in treating HTN associated with CKD?




Adamson  

Fishbane  

Singh  
New, Tri-Partite Approach to Anemia   
John W. Adamson, MD; Stephen Fishbane, MD; Ajay K. Singh, MB, MRCP; (Moderator: Jay Wish, MD).
(ASN Renal Week Official Symposium, 2006). Adamson: What controls iron accumulation in the liver? What is hepcidin, and how do hepcidin knockouts or gain of function mutations affect gut absorption of iron and release of iron from the RE system? Fishbane: What happens to ferritin and TSAT as GFR falls? What was the thinking behind the upper ferritin limit of 500 ng/mL in the KDOQI Workgroup? How is reduced serum iron during inflammation an adaptive response? How is hepcidin involved in all of this? What did the DRIVE study results show in terms of giving IV iron to patients with moderately elevated serum ferritin levels? Singh: Glycosylate, pegylate ... what are the strategies to increase ESA half-life? Why does CERA have such a long half-life? How is EPO receptor affinity involved? What is HIF? How does it affect EPO synthesis, and how do prolyl hydroxylase inhibitors affect HIF and EPO? How might hepcidin fit into this?



Annual Dialysis Conference 2006
now in MP3
AUDIOFILE LIST

Acute Renal Failure (ARF): State of the Art
Glen M. Chertow, MD, MPH; Emil P. Paganini, MD, FRCP; Claudio Ronco, MD; Joerg Vienken, DrEng; James F. Winchester, MD, FRCP, FACP

Infections in Dialysis
Norah Terrault, MD. MPH; Matthew J. Arduino, MS, DrPH; Michele Pearson, MD

K/DOQI 2006: Clinical Practice Guidelines for the Management of Anemia in Chronic Kidney Disease (CKD)
David B. Van Wyck, MD; Steven Fishbane, MD; Robert Foley, MB; Jeffrey Berns, MD

Advances in Understanding Endocrine Function in ESRD Patients
Martin Schreiber, MD; Isaac Teitelbaum, MD; Srikanth Gavini, MD



January 15th, 2007

Coyne  
Magnesium Balance: Hypomagnesemia and Hypermagnesemia   
Coyne: Where is magnesium stored in the body? What governs absorption by the GI tract? How is magnesium handled in the kidney? In what tubular segments is excretion regulated? What is the role of paracellin? Of the calcium-sensing receptor? Which diuretic class reduces magnesium excretion? What are the effects of Gitelman and Bartter syndromes? What are the important genetic abnormatlities? What are the consequences of hypopmagnesemia? How do we diagnose and treat? What are effects of hypermagnesemia, and how do we treat that? (ASN Board Review Course, 2006).




Foley  

Sica  
Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease   
Foley: How are classic and novel risk factors related to outcome in CKD patients as well as in dialysis patients? What can we learn from Framingham data? From NHANES? Which of the classical risk factors works in the opposite direction when GFR is low? To what extent have patients with mild-moderate CKD been excluded from the major cardiovascular trials? What can we learn from analysis of these subsets? How do the observational data differ from randomized, controlled trials?
Sica: How are the pathogenses of CKD and CVD (cardiovascular disease) related? Where do both impact the RAS (renin-angiotensin system)? How does ACE inhibition affect different parts of the cardiovascular system? What conclusions can we draw from AASK? How can we rationally choose drugs from different classes to treat hypertension? How should different calcium-blockers and ACE inhibitors be used in CKD? How do ACE inhibitors and ARBs compare? (ASN Renal Week Official Symposium, 2006).



Columbia University

Biopsy Conference: A middle-aged male with new onset nephrotic syndrome

(Columbia University Nephrology and Pathology Faculty; January, 2007)
A middle-aged male had hyperlipidemia, heavy smoking history, hypovitaminosis D, no DM, no HTN, no family history of renal disease. Taking furosemide, simvastatin, lisinopril, vitamin D. Presents with pedal edema and 13g/day proteinuria. Serum albumin is 2.2 g/dL. Complements and serologies are normal. Is it membranous GN? FSGS? Minimal change disease? Amyloidosis? Discussion focus: Thin basement nephropathy and membranous nephropathy.
(Edited by Jai Radhakrishnan, MD). (more...)



Annual Dialysis Conference 2006
now in MP3
AUDIOFILE LIST

Iron Management: We Can Do More!
Daniel W. Coyne, MD; Bradley Warady, MD; Jeffrey Petersen, MD, FRCP; David Leehey, MD; Jay Wish, MD

Understanding and Preventing Malnutrition in ESRD
Peter Stenvinkel, MD, PhD; Bengt Lindholm, MD, PhD; Jonas Axelsson, MD; Olof Heimbuerger, MD, PhD

The Physiology of High Transport
Olof Heimbuerger, MD, PhD; Raymond T. Krediet, MD, PhD; Bengt Lindholm, MD, PhD

Understanding, Preventing and Treating the MIA Syndrome in PD
Peter Stenvinkel, MD, PhD; Rajnish Mehrotra, MD, MBBS; Jonas Axelsson, MD

Peritoneal and Hemodialysis Catheters, Part II
Anatole Besarab, MD; Beth Piraino, MD; Garry Reams, MD



January 3rd, 2007

Bennett  
Transplantation: Medical and Immunosuppressive Management   
Bennett: What is the basis for the standard immunosuppression protocols in use currently? When do we use lymphocyte depleting agents or anti-IL2 monoclonal antibodies? How do we assess immunologic and non-immunologic risk and tailor immunosuppression accordingly? Which is better, cyclosporin or tacrolimus, and how is each drug best monitored? What is the basis for chronic allograft nephropathy, and how can we prevent and treat this? What is the state of knowledge regarding steroid avoidance or reduction regiments? When is it appropriate to reduce or eliminate calcineurin inhibitors from the mix? What are indications for expanded criteria donor kidneys? What are the transplant complications relating to osteoporosis, uric acid, and electrolyte disorders? How do we prevent or lower the risk for anemia and cancer? How do we approach fever in the transplant recipient? How do we treat polyomavirus nephropathy? What are the drug interactions among immunosuppressive medications? (ASN Board Review Course, 2006).




Sweeny  
Using Technology to Improve the Quality of Care (target audience: technicians)   
Sweeny: For those who did not know this, the National Association of Nephrology Technicians / Technologists has an excellent annual meeting. We are happy to archive one of the talks from the 2006 meeting focusing on technology by a person who has a long experience in the field. How has dialysis therapy evolved and how have membranes changed? What are the potential benefits of on-line hemodiafiltration and hemofiltration? What are the trends and challenges relating to use of ultrapure water for dialysis solution production? How can one practically implement a double-dialyzer solution to treat larger patients, both in-series and in-parallel? How does blood volume monitoring work and when is it useful? When is bioimpedance useful to determine patient fluid status? How can one measure clearance on-line using conductivity? What is being overlooked today and what are the keys to the future? Access to this talk is free for all members of NANT. Please contact the NANT office for the access code. (NANT Annual Meeting, 2006).




Annual Dialysis Conference 2006
now in MP3
AUDIOFILE LIST

Peritoneal and Hemodialysis Catheters, Part I
Michael Tal, MD; Ramesh Khanna, MD; W. Kirt Nichols, MD, MHA, FACS; Jack Work, MD

Frequent Dialysis: Does It Have to Be Daily?
Jos‚ A. Diaz-Buxo, MD, FACP; Frank A. Gotch, MD; Glen M. Chertow, MD, MPH; Christian Schlaeper, MS; Joseph Frost; Joe Pulliam, MD

Vascular Access
Emily Hodgin, BSN, RN, CNN, CPHQ; Anatole Besarab, MD; Lynda Ball, RN, BSN, CNN; Deborah J. Brouwer, RN, CNN; Lawrence Spergel, MD

Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients
Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD







HDCN home
/about our site / subscribe to key zone / register for free zone
update email address / subscription status / forget your password?